SCHEMBL2216170

SCHEMBL2216170

Cc1c(F)cc(C(=O)Nc2ccnn2C)cc1-c1cc2c(cn1)c(-c1ccc(F)cc1)nn2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NTRK1 P04629 1/20 0.38
GRM5 P41594 8/20 0.37
HPGDS O60760 1/20 0.37
CSNK1D P48730 3/20 0.36
CSNK1E P49674 3/20 0.36
MAPK14 Q16539 2/20 0.36
NAMPT P43490 2/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK11 Q15759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213762 0.87 MAPK1 (0.44)
SCHEMBL2217937 0.85 KDM4E (0.39) KDM4EALDH1A1TP53POLBMAPT
SCHEMBL2215646 0.80 CSNK1D (0.37) NTRK1HPGDSCSNK1DCSNK1EMAPK14
SCHEMBL2214625 0.79 MAPK14 (0.40) NTRK1HPGDSMAPK14CYP2C9MAPK11
SCHEMBL4221317 0.78 MAP2K4 (0.44)
SCHEMBL4739276 0.77 MAPK14 (0.46) NTRK1HPGDSMAPK14CYP2C9MAPK11
SCHEMBL4800075 0.72 MAPK14 (0.65) HPGDSMAPK14CYP2C9MAPK11
SCHEMBL2217082 0.72 MAPK14 (0.39) NTRK1HPGDSMAPK14CYP2C9MAPK11
SCHEMBL4738292 0.72 MAPK14 (0.65) POLBHPGDSMAPK14CYP2C9MAPK11
SCHEMBL2214850 0.72 MAPK14 (0.46) ALDH1A1POLBHPGDSMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
EP-1709046-B1 P38 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-07-27 EP disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed
US-20070161673-A1 P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161673-A1 P38 kinase inhibitors MAPK1, MAPK7, MAP3K1 KDM4E 4739/4885ALDH1A1 1403/4885TP53 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.